Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 19 recruiting now early-phase tilt

Tobacco Use Disorder: early-phase trial registry

19 of 75 indexed Tobacco Use Disorder trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #178 of 28,707 conditions by registered trial count.

75 US clinical trials · 19 currently recruiting · #178 of 28,707 conditions by registered trial count

Tobacco Use Disorder: 75 US clinical trials tracked, 19 recruiting.

Tobacco Use Disorder is the subject of 75 registered US clinical trials on ClinicalTrials.gov, 19 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 34 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute on Drug Abuse (NIDA), running 7 of these trials.

Enrollment posture brief

Registry condition tobacco-use-disorder

OPEN 19 | RECR 25% | LATE 9 | EARLY 34 | RANK #178 | SPON 7

Nearest open-share peer: Overweight (25% recruiting · 198 trials)

Acute Kidney Injury44%Infertility33.3%Age-related Macular Degenera26.7%Tobacco Use Disorder (this)25%Pulmonary Disease, Chronic O9.3%
Open-enrollment share among volume-matched conditions near Tobacco Use Disorder

Tobacco Use Disorder lists 19 open slots (25% of 75 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Tobacco Use Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Tobacco Use Disorder is recruiting below its size-band peers.

    19 of 75 indexed trials (25.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Tobacco Use Disorder trials is spread across many organizations.

    National Institute on Drug Abuse (NIDA) accounts for 7 of 75 trials (9.3%). 36 distinct sponsors appear on at least one study for this condition label.

  3. Typical Tobacco Use Disorder enrolment sits around 108 participants.

    Median target enrolment is 108 among the 71 trials that report a genuine target (sentinel values excluded). 32 of those (45.1%) plan for fewer than 100 participants.

  4. Tobacco Use Disorder research is mostly interventional.

    73 interventional and 2 observational studies make up this index (97.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 18Phase 226Phase 33Phase 46

Open and recent trials

75 total, page 1 of 2

RECRUITING NA 350 participants

Young Adult Tobacco/Nicotine and Cannabis Co-use

Medical University of South Carolina

NCT06239350

RECRUITING Phase 2 308 participants

Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes

University of Vermont

NCT06614504

RECRUITING Phase 3 200 participants

Cannabis-Tobacco Co-Use Treatment Study

Medical University of South Carolina

NCT06883162

RECRUITING NA 200 participants

Smoking Cessation Behavioral Treatment Study

University of Missouri-Columbia

NCT03948893

RECRUITING 200 participants

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

Yale University

NCT06624137

RECRUITING Phase 2 120 participants

Cannabidiol for Reducing Cigarette Use

University of California, Los Angeles

NCT06218056

RECRUITING NA 108 participants

Smoking Cessation CM for Veterans With or at Risk for Cancer

VA Office of Research and Development

NCT06432985

RECRUITING Phase 4 105 participants

E-cigarette Cessation in Adults Who Co-use Cannabis

Medical University of South Carolina

NCT06688539

RECRUITING Phase 4 80 participants

Beta-Adrenergic Modulation of Drug Cue Reactivity

University of Oklahoma

NCT05587361

RECRUITING NA 75 participants

Quit-Smoking Study for Native Hawaiians

University of Hawaii

NCT07075575

RECRUITING NA 70 participants

A Future Thinking Intervention for Comorbid Tobacco Use Disorder and Bipolar Disorder

Massachusetts General Hospital

NCT06609902

RECRUITING Phase 2 66 participants

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Johns Hopkins University

NCT05452772

RECRUITING Phase 2 64 participants

Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity

University of California, Los Angeles

NCT06617312

RECRUITING Phase 2 50 participants

Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD

VA Office of Research and Development

NCT05723588

RECRUITING Phase 1 50 participants

Oral Cannabidiol for Tobacco Cessation

Johns Hopkins University

NCT05445804

RECRUITING NA 44 participants

Low Intensity Focused Ultrasound for Tobacco Use Disorder: High Resolution Targeting of the Human Insula

Washington D.C. Veterans Affairs Medical Center

NCT06405074

RECRUITING NA 36 participants

Contingency Management for Veteran Smokers Undergoing Major Elective Surgery

University of California, San Francisco

NCT06678672

RECRUITING Phase 2 30 participants

An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction

University of Missouri-Columbia

NCT03713424

RECRUITING Phase 2 30 participants

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2

Yale University

NCT06006143

ACTIVE NOT RECRUITING Phase 4 631 participants

Varenicline and Combined NRT for Smoking Cessation

M.D. Anderson Cancer Center

NCT02271919

ACTIVE NOT RECRUITING Phase 2 400 participants

Omega-3 Fatty Acids for Smoking Cessation in Pregnancy

Vanderbilt University Medical Center

NCT04417595

ACTIVE NOT RECRUITING NA 338 participants

Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer

M.D. Anderson Cancer Center

NCT00542373

ACTIVE NOT RECRUITING NA 220 participants

Nicotine Replacement Therapy Prescribing and Lung Cancer Screening in Hospitalized Patients

Medical University of South Carolina

NCT07164404

ACTIVE NOT RECRUITING NA 120 participants

Developing an E-Cigarette Cessation Intervention for Hispanic/Latina(o) Youth in Florida: The BReATHE Study

Florida International University

NCT07192601

ACTIVE NOT RECRUITING NA 85 participants

Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation

M.D. Anderson Cancer Center

NCT02697227

ACTIVE NOT RECRUITING NA 26 participants

A Behavioral Activation Prenatal and Postpartum Intervention for Depressed Pregnant Smokers

M.D. Anderson Cancer Center

NCT05044546

ACTIVE NOT RECRUITING NA 24 participants

Use of a Smartphone Mobile Application (App) to Enhance Smoking Cessation Treatment

M.D. Anderson Cancer Center

NCT03519451

COMPLETED Phase 2 1,864 participants

Tobacco Zero: Interactive Tobacco Education for Teens

Deschutes Research

NCT00670995

COMPLETED Phase 2 1,683 participants

Effectiveness of a Web-Assisted Quitline for Smokeless Tobacco Users

Oregon Research Institute

NCT00820495

COMPLETED NA 943 participants

Integrating Clinical Practice Guidelines for Smoking Cessation Into Mental Health Care for Veterans With Posttraumatic Stress Disorder

US Department of Veterans Affairs

NCT00118534

COMPLETED NA 878 participants

Financial Incentives for Smoking Cessation

University of Pennsylvania

NCT00128375

COMPLETED Phase 4 837 participants

Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence

University of Rochester

NCT00178685

COMPLETED Phase 1 775 participants

Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders

Brown University

NCT02232737

COMPLETED Phase 1 775 participants

Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers

University of Vermont

NCT02250664

COMPLETED Phase 2 646 participants

Pharmacogenetics, Emotional Reactivity and Smoking

M.D. Anderson Cancer Center

NCT00507728

COMPLETED Phase 2 391 participants

Efficacy of Oral Tobacco Products Compared to a Medicinal Nicotine

University of Minnesota

NCT00710034

COMPLETED 350 participants

Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer

University of Minnesota

NCT01673711

COMPLETED Phase 2 326 participants

Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder

University of Vermont

NCT04092101

COMPLETED Phase 2 243 participants

Selegiline Patch for Treatment of Nicotine Dependence

Stanford University

NCT01330030

COMPLETED Phase 2 235 participants

Innovative Interventions for Smoking Cessation

University of Minnesota

NCT01050569

COMPLETED NA 213 participants

Cognitive Training for Nicotine Dependence

University of Pennsylvania

NCT01252966

COMPLETED Phase 3 200 participants

Naltrexone Augmentation of Nicotine Patch Therapy - 1

National Institute on Drug Abuse (NIDA)

NCT00218153

COMPLETED Phase 2 172 participants

Effectiveness of Bupropion for Treating Nicotine Dependence in Young People

National Institute on Drug Abuse (NIDA)

NCT00129272

COMPLETED NA 165 participants

A Facebook Intervention for Young Sexual and Gender Minority Smokers

University of California, San Francisco

NCT03259360

COMPLETED NA 162 participants

Intensive Intervention for Smokers - 6

University of California, San Francisco

NCT00217984

COMPLETED NA 158 participants

Innovative Digital Therapeutic for Smoking Cessation

My Digital Study

NCT03694327

COMPLETED Phase 2 152 participants

Reduction of Smoking in Cardiac Disease Patients

National Institute on Drug Abuse (NIDA)

NCT00469885

COMPLETED NA 148 participants

Effect of Black Raspberry Phytochemicals on Oral Microbiome in Current Smokers and Non-smokers

Ohio State University Comprehensive Cancer Center

NCT02439255

COMPLETED Phase 2 142 participants

Treatment of Smoking Among Individuals With PTSD

University of Pennsylvania

NCT00937235

COMPLETED Phase 2 138 participants

Effectiveness of Using Tobacco Free Snuff in Reducing Negative Effects of Smokeless Tobacco Use

National Institute on Drug Abuse (NIDA)

NCT00218270

Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 26
Phase 3 3
Phase 4 6

Named interventions

Most-linked intervention names on Tobacco Use Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Varenicline Drug
8 trials
Placebo Drug
6 trials
Nicotine Patch Drug
4 trials
Counseling Behavioral
3 trials
Questionnaire Administration Other
3 trials
Placebo Other
3 trials
Cotinine fumarate Drug
2 trials
Very low nicotine content cigarettes Other
2 trials

US sites by state

Facility locations filed on Tobacco Use Disorder trials. A trial with sites in several states counts in each.

Minnesota 15 trials
California 9 trials
Texas 8 trials
New York 7 trials
Maryland 7 trials
Connecticut 6 trials
South Carolina 5 trials
Pennsylvania 5 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Tobacco Use Disorder page

75 registered trials, 19 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Tobacco Use Disorder condition card totals 75 registered trials; most-linked intervention Varenicline; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.